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Abstract Self-monitoring of blood glucose in women with
mild gestational diabetes has recently been proven to be
useful in reducing the rates of fetal overgrowth and
gestational weight gain. However, uncertainty remains with
respect to the optimal frequency and timing of self-
monitoring. A continuous glucose monitoring system may
have utility in pregnant women with insulin-treated diabe-
tes, especially for those women with blood sugars that are
difficult to control or who experience nocturnal hypogly-
cemia; however, continuous glucose monitoring systems
need additional study as part of larger, randomized trials.
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Introduction
An association between diabetes in pregnancy and fetal
overgrowth has long been recognized. Fetal overgrowth is
associated with a number of adverse outcomes for both the
mother and her baby, such as a higher rate of difficult
delivery. To reduce the rate of fetal overgrowth and its
associated complications, women with diabetes in pregnan-
cy undergo a number of interventions. Among these
interventions is glucose monitoring. Although glucose
monitoring during pregnancies complicated by diabetes
mellitus is widely practiced, it is important to ask a number
of questions:
1. Is there evidence that glucose monitoring improves
outcomes in women with gestational diabetes?
2. Which glycemic parameters are associated with adverse
pregnancy outcomes and are therefore best used in
management?
3. What cutoffs for normal and abnormal glucose values
are appropriate in a glucose monitoring regimen?
4. What is the utility of measuring glycosylated hemoglo-
bin during gestation?
5. Is a continuous glucose monitoring system (CGMS)
beneficial?
In answering these questions, this article focuses on
recent articles that appeared between 2007 and 2009. A
PubMed search using the terms “diabetes” and “pregnancy”
was used to select relevant studies.
Is There Evidence That Glucose Monitoring Improves
Outcomes in Women With Gestational Diabetes?
With the advent of home reflectance monitors in the late
1970s and early 1980s, self-monitoring of blood glucose
(SMBG) was demonstrated to be possible, and perhaps
beneficial, in women with gestational diabetes [1, 2]. By
2004, SMBG was widely practiced, with more than 90% of
obstetrician/gynecologists recommending that their patients
with gestational diabetes check fasting blood glucose
(FBG). However, only 61% of obstetrician/gynecologists
were recommending 2-hour postprandial tests [3]. This lack
of uniformity in the approach to glucose monitoring can be
attributed to several factors. Specifically, there has been
uncertainty about the frequency and utility of daily testing;
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the necessity of SMBG in all women with diabetes during
pregnancy; the timing of self-monitoring measurements and
whether preprandial or postprandial testing was superior;
and the ideal thresholds for implementing changes in
therapy [4].
With respect to the uncertain benefits of SMBG in
women with diet-treated gestational diabetes, we recently
published our findings regarding the utility of SMBG at the
University of Texas Southwestern Medical Center [5].
Between January 1991 and December 1997, women with
diet-treated gestational diabetes had routine glycemic
monitoring at weekly prenatal visits [5]. After January
1998, the standard practice was to issue home glucose
meters with instructions to check blood glucose levels four
times per day. A total of 675 women who underwent
weekly monitoring were compared with 315 women who
performed SMBG four times per day. We found that SMBG
was associated with a number of maternal and fetal
benefits. In particular, there were significantly fewer
overgrown infants, with rates of macrosomic and large-
for-gestational-age infants at 21.9% and 23.1%, respective-
ly, among women using SMBG, compared with 29.9% and
34.4%, respectively, for women monitored weekly (P
values, 0.013 and ≤0.001, respectively). Women using
SMBG gained significantly less weight when compared
with women monitored weekly. Women using self-
monitoring gained a median of 0.56 lb per week (inter-
quartile range, 0.22–1.08) compared with 0.74 lb per week
(interquartile range, 0.33–1.17; P=0.009) when compared
with women monitored weekly. Given that there is an
association between excessive gestational weight gain and
postpartum weight retention [6] with all of its potential
long-term sequelae, it seems prudent to incorporate preg-
nancy interventions that limit weight gain.
These data are supported by the recent findings of Wilson
et al. [7], who compared two cohorts composed of 50
randomly selected patients from the 2000–2002 and 2006–
2008 epochs. The intention of the authors was to assess the
effect of three interventions incorporated into routine
prenatal care for women with diet-treated gestational
diabetes at their institution between 2003 and 2005. These
three interventions included dietary advice, regular contact
with a diabetic team, and 1-hour postprandial SMBG (with a
glycemic target ≤7.8 mmol/L). Although it may be difficult
to separate the effect of dietary advice and contact with the
diabetic team from the effect of glucose monitoring, the
cumulative benefit was a reduction in neonatal birth weights
for women who received these interventions, including
SMBG (3,269 vs. 3,567 g; P=0.033).
Recent expert opinion also supports the utility of SMBG
in women with gestational diabetes. Writing in Endocrine
Practice, Dr. Jovanovic [8] emphasized the importance of a
self-monitoring regimen incorporating postprandial glucose
determination because postprandial hyperglycemia has been
correlated with fetal overgrowth. Dr. Jovanovic advocates
an intensive approach and recommends self-monitoring
four times per day in patients with diet-treated gestational
diabetes, and six times per day in women with insulin-
treated gestational diabetes. Other experts also emphasize
the importance of SMBG by women with gestational
diabetes [9] and pregestational diabetes [10].
Which Glycemic Parameters Are Associated
With Adverse Pregnancy Outcomes and Therefore
Are Best Used in Management?
Several glycemic parameters can be considered for glucose
monitoring in women with gestational diabetes. The recent
evidence for fasting, postprandial, and preprandial glucose
values are each discussed in turn.
Fasting blood sugar is a valuable glycemic parameter for
assessing the risk of undesirable pregnancy outcomes.
Recently, Gonzalez-Quintero et al. [11] compared 2,030
women with gestational diabetes and good glucose control
to 1,188 women with gestational diabetes but with poor
glucose control. The percentage of patients with the
composite outcome (defined as one or more of the
following: macrosomia, large for gestational age, stillbirth,
neonatal hypoglycemia, or jaundice) more than doubled
(57.9% vs. 24.8%) with an FBG of at least 123.5 mg/dL,
compared with FBG levels less than 95 mg/dL. Voldner et
al. [12] also found that fasting plasma glucose is a
significant determinant of macrosomia (OR, 1.9; 95% CI,
1.1–3.4), especially for women with a body mass index of
at least 27 kg/m2. Such women had an OR of 4.5 (95% CI,
1.7–12.5) for neonates with macrosomia.
These latter findings are consistent with the results of
several recent studies assessing the effect of FBG measured
during initial glucose tolerance testing. Seshiah et al. [13]
screened 12,056 consecutive women and reported that the
risk of delivering a large-for-gestational-age neonate rose
with FBG levels above 80 mg/dL, and was significantly
increased above 90 mg/dL. Additionally, Riskin-Mashiah et
al. [14] studied 6,129 women who underwent glucose
tolerance testing in the first trimester, but who did not have
pregestational diabetes or FBG values greater than 105mg/dL.
There was an increasing risk of large-for-gestational-age or
macrosomic infants with rising FBG values above 75 mg/dL,
and these risks were significant above 80 mg/dL. Likewise,
the HAPO (Hyperglycemia and Adverse Pregnancy Out-
comes) trial [15••] of 23,316 women reported the blinded
results of 75-g glucose tolerance testing performed from 24
to 32 weeks’ gestation. This landmark study showed that
there were continuous associations between increasing
maternal glucose levels (fasting as well as at 1- and 2-hours
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postprandial) and birth weight. However, the reference group
was composed of women with fasting glucose values less
than 75 mg/dL, a measurement substantially less than the
present threshold for diagnosis of gestational diabetes. As the
accompanying editorial for the HAPO trial noted, it is
questionable whether lowering the threshold for the diagnosis
and treatment of gestational diabetes would confer a benefit,
without also potentially increasing the risk of poor fetal
growth [16].
Recent evidence supports the contention by prominent
investigators that postprandial hyperglycemia is a critical
determinant in the development of the oversized fetus [8],
but these recent data also suggest that preprandial hyper-
glycemia is similarly a factor in fetal overgrowth. Herranz
et al. [17] studied 73 women with type 1 diabetes mellitus
in pregnancy who were monitored six times daily during
preconception and throughout pregnancy. Postprandial
hyperglycemia, as well as preprandial hyperglycemia, were
noted to be important variables in determining fetal size,
with adjusted ORs of 2.03 (95% CI, 1.14–3.60) and 2.97
(95% CI, 1.31–6.73), respectively. In another study of 70
women with type 1 diabetes mellitus, preprandial hyper-
glycemia was again noted to be an important variable in
determining fetal size [18]. In particular, preprandial
hyperglycemia between weeks 29 and 32 was a strong
predictor of a large-for-gestational-age infant. It remains
unproven whether the combination of both preprandial and
postprandial monitoring is superior to either preprandial or
postprandial monitoring alone in women with diabetes
during pregnancy.
Although a number of different glucose parameters have
been shown to be helpful in the glucose monitoring of
women with gestational diabetes, recent evidence exists to
support the practice of most investigators who check fasting
and postprandial glucose values [3]. However, with respect
to postprandial glucose monitoring, it remains unclear
whether 2-hour postprandial values are superior to 1-hour
postprandial glucose values.
What Cutoffs for Normal and Abnormal Glucose Values
Are Acceptable in a Glucose Monitoring Regimen?
Dr. John B. O’Sullivan’s pioneering work from the late
1950s through the 1970s demonstrated that gestational
diabetes is associated with a number of adverse outcomes
[19, 20]. He also showed that intervening to reduce
hyperglycemia could reduce the number of overgrown
babies [21]. Dr. O’Sullivan established the criteria for the
diagnosis of gestational diabetes by measuring glucose
values using the Somogyi-Nelson method on whole venous
blood in 752 pregnant women [22]. He then set an upward
normal limit of less than two standard deviations from the
mean for the fasting and 1, 2, and 3-hour postprandial
values [22]. In subsequent years, the method used to
measure glucose changed from a venous blood–based
system to a plasma-based system using glucose oxidase
technology, resulting in values that were approximately
14% higher. Thus, in 1979, when the National Diabetes
Data Group made recommendations for the diagnosis of
gestational diabetes, the cutoff values that Dr. O’Sullivan
had earlier reported were changed to 105, 190, 165, and
145 mg/dL [23]. Subsequently, Carpenter and Coustan
recommended lower values (95, 180, 155, and 140 mg/dL)
using a different algorithm to account for reducing
substances [24].
The fasting value as recommended by the National
Diabetes Data Group (105 mg/dL) and the fasting value as
determined by Carpenter and Coustan (95 mg/dL) form the
basis for the current recommended fasting values. Either
value is acceptable for the diagnosis of gestational diabetes
according to the most recent Practice Bulletin by the
American College of Obstetricians and Gynecologists
(ACOG) [4], although ACOG does suggest that a fasting
value of 95 mg/dL be used as the criteria for initiating or
changing insulin therapy in women with gestational
diabetes [4], as well as pregestational diabetes [25]. For
monitoring during labor and delivery, glucose is generally
checked hourly, and insulin is started for a capillary blood
glucose of 100 mg/dL or greater [26].
What Is the Utility of Monitoring Glycosylated
Hemoglobin During Gestation?
The glycosylated hemoglobin concentration, also called
hemoglobin A1c, reflects a longer duration of glycemic
control, generally about 3 months, which approximates the
life span of the red blood cell. The use of this glycemic
parameter has not been as widely incorporated into the
management of diabetes mellitus during pregnancy, because
it does not reflect short-term glycemic variations that occur
due to changes in diet or insulin therapy. However, it has
been tested as a variable in recent studies for estimating
risks of three separate adverse outcomes: congenital
malformations, preterm birth, and overgrown infants. With
respect to the risk of malformations, a recent review of
seven prospective cohort studies by Guerin et al. [27]
revealed an increasing risk of major and minor anomalies
with rising hemoglobin A1c concentrations. With respect to
the risk of preterm birth, Ekbom et al. [28] reported rising
rates of preterm birth according to hemoglobin A1c
measured at 28 weeks’ gestation among 213 women with
type 1 diabetes mellitus. In particular, the risk of sponta-
neous preterm birth increased substantially for every 1%
rise in hemoglobin A1c, with an adjusted OR of 4.5 (95%
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CI, 2.0–9.8). However, glycosylated hemoglobin values
have shown less utility for assessing the risk of
overgrown infants, as two recent reports indicate. First,
Lapolla et al. [29] reported that hemoglobin A1c was not a
useful predictor of large-for-gestational-age or macro-
somic newborns in their review of 611 women with
hemoglobin A1c measured between 24 weeks and 27 weeks
of gestation. In another study, Kernaghan et al. [30]
actually reported a negative correlation between hemoglo-
bin A1c and birth weight among 338 women with type 1
diabetes mellitus.
In summary, the utility of a hemoglobin A1c value
appears to be greatest when performed periconceptionally
to estimate the risk of congenital anomalies, but it does not
appear to confer substantial benefit for estimating the risk
of fetal overgrowth or other adverse pregnancy outcomes.
Is a Continuous Glucose-Monitoring System Beneficial?
Continuous glucose monitoring in women with diabetes
during pregnancy has provoked considerable recent inter-
est, with no less than five clinical trials [31–35] and five
reviews [36, 37, 38•, 39, 40] published since 2007. This
interest undoubtedly stems from the additional information
that a CGMS provides. By taking readings throughout the
day (every 10 s, then averaging these readings over 5 min),
continuous glucose monitoring is thought to provide a more
complete picture of interprandial glycemic variability.
However, it has been unclear whether the 288 readings
generated during a 24-hour period can improve clinical
management. Moreover, continuous monitoring requires the
uninterrupted insertion of a glucose oxidase tip into the
subcutaneous tissue of the anterior abdominal wall to
measure the glucose levels of interstitial fluid. Continuous
glucose monitoring is thus considerably more invasive than
traditional SMBG. The commentary by Charlton [41]
details the practical aspects of how these devices function,
as well as the perceived advantages and disadvantages of
CGMS.
A recent pilot study was reported from an institution
interested in the feasibility of continuous glucose monitor-
ing. To assess the tolerability and utility of the Medtronic
CGMS (Medtronic, Minneapolis, MN), McLachlan et al.
[33] evaluated 55 women with diabetes during pregnancy.
The majority of the participants were women with
gestational diabetes (37 of 55), with the balance of patients
divided between type 2 (n=10) and type 1 diabetes (n=8).
Subjects who were assessed as having difficult glycemic
control were issued a continuous glucose monitor, and most
of these women completed at least 97% of the 72-hour
monitoring period. The objective of this monitoring was to
obtain feedback from the perspective of both the patient and
the treating clinician. In a follow-up feedback question-
naire, 37 of the 48 patients who responded (77%) felt that
the benefits of using a CGMS outweighed the risk, with
92% reporting that the device was “very easy” or “easy” to
use and 81% reporting that the inconvenience was minimal
or minor. Similarly, most (62%) of the treating clinicians
surveyed felt that the additional information was clinically
useful and altered management, either by revealing over-
night hypoglycemia (especially in type 1 diabetes) or by
indicating the presence of hyperglycemia that was unde-
tected by concurrent intermittent SMBG.
However, two recent comparative trials have not
reported dramatic benefits for CGMS over SMBG. Both
of these trials used an open-label, randomized, controlled
design to directly compare CGMS with daily SMBG. In the
first study by Kestila et al. [32], 36 women with gestational
diabetes were randomized to CGMS (Medtronic) and 37
women to SMBG. Of these women, 31% in the CGMS
group were ultimately prescribed insulin, metformin, or
both, compared with only 8% of the SMBG group
prescribed such therapy (P=0.0149). Nonetheless, this
additional antihyperglycemic therapy in the CGMS group
did not translate into a benefit with respect to maternal or
neonatal outcomes. In particular, there was no reduction in
the rates of cesarean delivery or hypertension for women
with gestational diabetes using the continuous monitoring
system, nor was there any reduction in birth weight or rates
of neonatal hypoglycemia. Apart from women with
gestational diabetes, Murphy et al. [34] examined the effect
of a CGMS on pregnant women with type 1 diabetes (46
women) or type 2 diabetes (25 women). These women were
randomized to a CGMS (Medtronic) plus standard antenatal
therapy (CGMS + SMBG, 38 women) or to standard
antenatal therapy (SMBG, 33 women). There were more
women with type 1 diabetes versus type 2 diabetes (74%
vs. 55%) in the CGMS group, and this translated into a
significantly greater mean duration of diabetes in the
CGMS group (15.2 vs. 10.0 years; P=0.03). These women
in the CGMS group ultimately delivered significantly
smaller babies as measured by median birth weight centile
(69th vs. 93rd; P=0.02), but the P values for the rates of
macrosomia (Q90th centile) and the mean birth weight
standard deviation score were barely significant at 0.05.
Moreover, there were no significant differences in the rates
of extremely large-for-gestational-age (Q97.7th centile) neo-
nates, cesarean delivery, preeclampsia, or other measures of
neonatal morbidity.
Two smaller, noncomparative studies assessed the
effect of a CGMS during labor. Stenninger et al. [35]
prospectively studied the use of a Medtronic CGMS in 15
women with insulin-treated diabetes during labor and
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delivery. The authors found that glucose levels in the 2 h
prior to delivery correlated with the need for intravenous
glucose therapy in the neonates, and they also reported
that “the mothers coped well with the CGMS recording
during labor.” Similarly, Iafusco et al. [31] used a
Medtronic CGMS during labor and delivery, as well as
during betamethasone treatment for imminent preterm
delivery in 18 women with type 1 diabetes. On the basis
of this glycemic evaluation, decisions to begin insulin
therapy were made, and the authors reported that were no
cases of neonatal hypoglycemia or respiratory distress
syndrome after delivery.
In summary, recent studies suggest that CGMS may be
beneficial for certain women with diabetes treated with
insulin, particularly in women with diabetes that is difficult
to control. However, these data require further evaluation
and do not yet support the incorporation of CGMS into
routine practice. For an evaluation of all studies incorpo-
rating CGMS since 1999, the reader is directed to the
comprehensive reviews by De Block et al. [38•] and Block
et al. [39].
Conclusions
Although of proven value in the management of women
with overt diabetes, SMBG in women with mild gestational
diabetes has only recently been proven to be useful in
reducing the rates of fetal overgrowth and gestational
weight gain. Yet, there remains uncertainty about the
optimal frequency and timing of self-monitoring. The
ACOG recommends that a value of 95 mg/dL be used as
a threshold for fasting hyperglycemia [4, 25]. The utility of
testing glycosylated hemoglobin is limited to periconcep-
tual measurements in evaluating the risk of congenital
anomalies. A CGMS may have value in pregnant women
with insulin-treated diabetes, especially for those whose
blood sugars are difficult to control or may have nocturnal
hypoglycemia, but this technology needs additional evalu-
ation with larger, randomized, controlled trials.
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